# Cytokinetics Inc: overview

CYTK · Nasdaq · CIK 1061983 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cytk.md) · [Financials](/companies/cytk/financials.md) · [Filings](/companies/cytk/filings.md) · [Insiders](/companies/cytk/insiders.md)

Latest reported revenue: [$28.6m](/filings/0001193125-26-338217.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-338217).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.5](/filings/0001193125-25-267059.md) | [16.9 d](/filings/0001193125-26-076495.md) | [1.6](/filings/0001193125-26-206364.md) | [66.8](/filings/0001193125-26-338217.md) | [1.9](/filings/0001193125-25-267059.md) | [17.8 d](/filings/0001193125-26-076495.md) | [19.4](/filings/0001193125-26-206364.md) | [28.6](/filings/0001193125-26-338217.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(30410.6%)](/filings/0001193125-25-267059.md) | [(821.4%) d](/filings/0001193125-26-076495.md) | [(9856.3%)](/filings/0001193125-26-206364.md) | [(167.0%)](/filings/0001193125-26-338217.md) | [(8613.4%)](/filings/0001193125-25-267059.md) | [(1004.6%) d](/filings/0001193125-26-076495.md) | [(948.7%)](/filings/0001193125-26-206364.md) | [(626.0%)](/filings/0001193125-26-338217.md) |
| Net margin | % | [(34674.9%)](/filings/0001193125-25-267059.md) | [(886.3%) d](/filings/0001193125-26-076495.md) | [(10220.1%)](/filings/0001193125-26-338217.md) | [(201.2%)](/filings/0001193125-26-338217.md) | [(15815.0%)](/filings/0001193125-25-267059.md) | [(1030.9%) d](/filings/0001193125-26-076495.md) | [(1064.5%)](/filings/0001193125-26-338217.md) | [(694.4%)](/filings/0001193125-26-338217.md) |
| Diluted EPS | $ per share | [(1.36)](/filings/0001193125-25-267059.md) | not reported | [(1.36)](/filings/0001193125-26-206364.md) | [(1.12)](/filings/0001193125-26-338217.md) | [(2.55)](/filings/0001193125-25-267059.md) | not reported | [(1.67)](/filings/0001193125-26-206364.md) | [(1.50)](/filings/0001193125-26-338217.md) |
| Free cash flow | $m | [(102) d](/filings/0001193125-25-267059.md) | [(66.9) d](/filings/0001193125-26-076495.md) | [(137)](/filings/0001193125-26-206364.md) | [(132) d](/filings/0001193125-26-338217.md) | [(117) d](/filings/0001193125-25-267059.md) | [(148) d](/filings/0001193125-26-076495.md) | [(151)](/filings/0001193125-26-206364.md) | [(164) d](/filings/0001193125-26-338217.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [70.4](/filings/0000950170-24-022256.md) | [94.6](/filings/0000950170-25-029206.md) | [7.5](/filings/0001193125-26-076495.md) | [18.5](/filings/0001193125-26-076495.md) | [88.0](/filings/0001193125-26-076495.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(264.5%)](/filings/0000950170-24-022256.md) | [(342.8%)](/filings/0000950170-25-029206.md) | [(6589.7%)](/filings/0001193125-26-076495.md) | [(2902.7%)](/filings/0001193125-26-076495.md) | [(695.4%)](/filings/0001193125-26-076495.md) |
| Net margin | % | [(305.7%)](/filings/0000950170-24-022256.md) | [(411.2%)](/filings/0000950170-25-029206.md) | [(6988.6%)](/filings/0001193125-26-076495.md) | [(3191.1%)](/filings/0001193125-26-076495.md) | [(891.6%)](/filings/0001193125-26-076495.md) |
| Diluted EPS | $ per share | [(2.80)](/filings/0000950170-24-022256.md) | [(4.33)](/filings/0000950170-25-029206.md) | [(5.45)](/filings/0001193125-26-076495.md) | [(5.26)](/filings/0001193125-26-076495.md) | [(6.54)](/filings/0001193125-26-076495.md) |
| Free cash flow | $m | [(191)](/filings/0000950170-24-022256.md) | [(311)](/filings/0000950170-25-029206.md) | [(416)](/filings/0001193125-26-076495.md) | [(400)](/filings/0001193125-26-076495.md) | [(535)](/filings/0001193125-26-076495.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cytk/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.71bn | 20,094,362 |  | Added +3,546,351 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $590.5m | 6,931,770 |  | Reduced −1,077,719 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $571.8m | 6,711,799 |  | Added +868,017 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $553.2m | 6,494,233 |  | Added +749,040 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $521.2m | 6,117,515 |  | Added +628,881 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $428.7m | 5,031,782 |  | Reduced −5,691,358 |
| [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $425.9m | 4,999,999 |  | Added +1,666,666 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $394.9m | 4,635,709 |  | Added +1,510,273 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $316.3m | 3,712,501 |  | Added +497,086 |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $243.8m | 2,862,003 |  | Added +140,845 |

## Recent filings

[All 2,050 filings](/companies/cytk/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-28 | 13:21 ET | [8-K](/filings/0001193125-26-372456.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-372456 |
| 2026-08-13 | 13:25 ET | [8-K](/filings/0001193125-26-348060.md) | 8.01 Other events | 0001193125-26-348060 |
| 2026-08-06 | 20:30 ET | [10-Q](/filings/0001193125-26-338217.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338217 |
| 2026-08-06 | 20:11 ET | [8-K](/filings/0001193125-26-338021.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338021 |
| 2026-05-27 | 20:00 ET | [8-K](/filings/0001193125-26-241840.md) | 5.07 Shareholder vote results | 0001193125-26-241840 |
| 2026-05-08 | 20:05 ET | [8-K](/filings/0001193125-26-214606.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-214606 |
| 2026-05-05 | 20:12 ET | [8-K](/filings/0001193125-26-206420.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-206420 |
| 2026-05-05 | 20:06 ET | [10-Q](/filings/0001193125-26-206364.md) | Quarterly report, period 2026-03-31 | 0001193125-26-206364 |
| 2026-05-05 | 20:05 ET | [8-K](/filings/0001193125-26-206360.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-206360 |
| 2026-04-17 | 20:05 ET | [DEF 14A](/filings/0001140361-26-015364.md) | Proxy statement, period 2026-05-27 | 0001140361-26-015364 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076495.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ebfc6ce8-c783-42f2-a509-3b8c48717083)

## About the filer

- CIK: 1061983
- Tickers: CYTK
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.